|174.63||+8.87 / +5.35%|
Data as of Jan 26
|174.00||-0.63 / -0.36%|
The 16 analysts offering 12-month price forecasts for Intercept Pharmaceuticals Inc have a median target of 457.50, with a high estimate of 650.00 and a low estimate of 175.00. The median estimate represents a +161.98% increase from the last price of 174.63.
The current consensus among 16 polled investment analysts is to Buy stock in Intercept Pharmaceuticals Inc. This rating has held steady since January, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.